PRINCETON, N.J. - Bristol Myers Squibb (NYSE: BMY), a prominent pharmaceutical company with a market capitalization of nearly $120 billion and impressive gross profit margins of 76%, received a ...

T-cells from the liver and lymph nodes show promising potential for future treatments of liver cancer, according to a new ...

A sensation of fullness beneath the ribs on the right side A similar feeling under the ribs on the left side Yellowing of the ...

SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

Researchers at the Terasaki Institute for Biomedical Innovation have developed an innovative delivery system that could significantly improve the effectiveness of peptide-based cancer vaccines, ...

Researchers at the Terasaki Institute for Biomedical Innovation have developed an innovative delivery system that could significantly improve the effectiveness of peptide-based cancer vaccines, ...

January 28, 2025 - Researchers at the Terasaki Institute for Biomedical Innovation have developed an innovative delivery system that ...

The LEAP-015 study is evaluating Merck's Keytruda and Eisai's Lenvima plus chemotherapy in certain types of gastroesophageal ...

Adding camrelizumab and rivoceranib to transarterial chemoembolization (TACE) significantly prolonged progression-free ...

Opdivo plus Yervoy shows efficacy and manageable safety as first-line treatment for unresectable hepatocellular carcinoma in ...

MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but ...

Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and chemotherapy improved progression-free survival but did not achieve statistical significance for overall survival in patients with advanced ...